Severity of cerebral palsy and incidence of adverse events following botulinum toxin A injections

Karen Bau; C Swinney; Karen Oakley; S O'Flaherty; Simon Paget

doi:10.1111/dmcn.02_13512

Severity of cerebral palsy and incidence of adverse events following botulinum toxin A injections

Karen Bau, C Swinney, Karen Oakley, S O'Flaherty, Simon Paget

Research output: Contribution to conference (non-published works) › Abstract › peer-review

Abstract

Background and Objective(s): Botulinum toxin A (BoNT-A) is a well-established treatment for hypertonia in children with cerebral palsy (CP). The incidence of adverse events (AE) following BoNT-A has been estimated as 3.3–7.4%. This study aims to identify if severity of CP correlates with incidence of severe adverse events after BoNT-A.

Original language	English
Pages	80-80
Number of pages	1
DOIs	https://doi.org/10.1111/dmcn.02_13512
Publication status	Published - 24 Aug 2017
Externally published	Yes
Event	71st Annual Meeting of the American Academy for Cerebral Palsy and Developmental Medicine (AACPDM) - Montreal, Montreal, Canada Duration: 13 Jun 2017 → 16 Jun 2017

Conference

Conference	71st Annual Meeting of the American Academy for Cerebral Palsy and Developmental Medicine (AACPDM)
Country/Territory	Canada
City	Montreal
Period	13/06/17 → 16/06/17

Access to Document

10.1111/dmcn.02_13512

Cite this

@conference{be44feb9b1464eae9a8dd01541ec13b3,

title = "Severity of cerebral palsy and incidence of adverse events following botulinum toxin A injections",

abstract = "Background and Objective(s): Botulinum toxin A (BoNT-A) is a well-established treatment for hypertonia in children with cerebral palsy (CP). The incidence of adverse events (AE) following BoNT-A has been estimated as 3.3–7.4%. This study aims to identify if severity of CP correlates with incidence of severe adverse events after BoNT-A.",

author = "Karen Bau and C Swinney and Karen Oakley and S O'Flaherty and Simon Paget",

year = "2017",

month = aug,

day = "24",

doi = "10.1111/dmcn.02_13512",

language = "English",

pages = "80--80",

note = "71st Annual Meeting of the American Academy for Cerebral Palsy and Developmental Medicine (AACPDM) ; Conference date: 13-06-2017 Through 16-06-2017",

}

Severity of cerebral palsy and incidence of adverse events following botulinum toxin A injections. / Bau, Karen; Swinney, C; Oakley, Karen et al.
2017. 80-80 Abstract from 71st Annual Meeting of the American Academy for Cerebral Palsy and Developmental Medicine (AACPDM), Montreal, Canada.

Research output: Contribution to conference (non-published works) › Abstract › peer-review

TY - CONF

T1 - Severity of cerebral palsy and incidence of adverse events following botulinum toxin A injections

AU - Bau, Karen

AU - Swinney, C

AU - Oakley, Karen

AU - O'Flaherty, S

AU - Paget, Simon

PY - 2017/8/24

Y1 - 2017/8/24

N2 - Background and Objective(s): Botulinum toxin A (BoNT-A) is a well-established treatment for hypertonia in children with cerebral palsy (CP). The incidence of adverse events (AE) following BoNT-A has been estimated as 3.3–7.4%. This study aims to identify if severity of CP correlates with incidence of severe adverse events after BoNT-A.

AB - Background and Objective(s): Botulinum toxin A (BoNT-A) is a well-established treatment for hypertonia in children with cerebral palsy (CP). The incidence of adverse events (AE) following BoNT-A has been estimated as 3.3–7.4%. This study aims to identify if severity of CP correlates with incidence of severe adverse events after BoNT-A.

U2 - 10.1111/dmcn.02_13512

DO - 10.1111/dmcn.02_13512

M3 - Abstract

SP - 80

EP - 80

T2 - 71st Annual Meeting of the American Academy for Cerebral Palsy and Developmental Medicine (AACPDM)

Y2 - 13 June 2017 through 16 June 2017

ER -

Severity of cerebral palsy and incidence of adverse events following botulinum toxin A injections

Abstract

Conference

Access to Document

Fingerprint

Cite this